1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support innovative startups and small and medium-sized enterprises (SMEs) that aim to develop and scale groundbreaking technologies. This initiative plays a crucial role in the European DeepTech ecosystem by providing financial support through grants and equity investments, thereby fostering innovation and contributing to the European economy.

Funding Structure

The EIC Accelerator offers two main types of funding: grants and equity investments.

The EIC Accelerator aims to bridge the funding gap that many startups face, particularly in the high-risk phases of development and commercialization. By providing both grants and equity investments, the program helps companies attract further funding from private investors, thereby enhancing their growth potential.

Purpose and Impact on the European DeepTech Ecosystem

The EIC Accelerator plays a pivotal role in the European DeepTech and startup ecosystem by:

• Supporting Innovation: It encourages the development of cutting-edge technologies that can solve complex societal challenges.
• Enhancing Competitiveness: By funding high-potential startups, the program strengthens Europe's position in the global technology landscape.
• Facilitating Market Entry: The funding provided enables companies to bring their innovative solutions to market more quickly and effectively, thereby driving economic growth.
• Leveraging Private Investment: The EIC Accelerator's financial support helps startups demonstrate their viability to private investors, making it easier for them to secure additional funding.

Case Study: NIMBLE DIAGNOSTICS SL and the NIMBLE System

Company Overview: NIMBLE DIAGNOSTICS SL, based in Spain, is a pioneering company that has developed a groundbreaking medical device aimed at improving patient care in the cardiovascular sector.

Project Acronym: NIMBLE System

Project Description: The NIMBLE System is a novel, non-invasive, and non-ionizing medical device designed for the continuous monitoring of patients with implanted cardiovascular stents. This technology is particularly significant for patients who require ongoing surveillance to ensure the functionality of their stents, which are critical for maintaining blood flow and preventing complications.

Funding Achievement: NIMBLE DIAGNOSTICS SL successfully secured EIC Accelerator funding through a Step 2 proposal submitted on June 21, 2023, culminating in a Step 3 interview that led to funding approval.

Technological Background of the NIMBLE System

The NIMBLE System leverages advanced sensor technology and data analytics to monitor patients' cardiovascular health continuously. Key features include:

• Non-Invasive Monitoring: The device employs techniques that do not require invasive procedures, making it safer for patients and reducing hospital visits.
• Real-Time Data Collection: Continuous monitoring allows for the timely detection of potential complications, enabling healthcare providers to intervene promptly.
• Non-Ionizing Technology: Unlike traditional imaging techniques that expose patients to ionizing radiation, the NIMBLE System utilizes non-ionizing methods, ensuring patient safety.
• Integration with Healthcare Systems: The device is designed to seamlessly integrate into existing healthcare infrastructure, facilitating data sharing and improving clinical workflows.

The NIMBLE System represents a significant advancement in cardiovascular care, addressing the critical need for improved monitoring solutions for patients with stents. By receiving EIC Accelerator funding, NIMBLE DIAGNOSTICS SL is well-positioned to accelerate the development and deployment of this innovative technology, ultimately enhancing patient outcomes and contributing to the broader healthcare landscape in Europe.

2 The Funding Rounds

Nimble Diagnostics SL: Financing and Funding Overview Since EIC Accelerator Award (Spain)

Nimble Diagnostics SL, a Spanish MedTech spin-off, has raised significant funding and recognition since submitting its successful Step 2 proposal for the EIC Accelerator on June 21, 2023. The company specializes in non-invasive monitoring technologies for cardiovascular stent patients.

---

Financing Raised

EIC Accelerator Grant:

In late October 2023, Nimble Diagnostics secured a €2.5 million grant from the European Innovation Council’s EIC Accelerator program. This funding supports technology development, team expansion, prototyping completion, and their first European clinical trial.

Private Funding Round:

Prior to or concurrent with the EIC grant announcement, Nimble Diagnostics closed a private round of over €1 million. This round was led by Grow Venture Partners with participation from Namarel Ventures and Inveniam Group.

---

Funding Rounds: Timing and Amounts

Date	Type	Amount	Lead Investors/Source
~Oct/Nov 2023	Public Grant	€2.5 million	EIC Accelerator (European Innovation Council)
Announced Q4 2023	Private Equity Round	>€1 million	Grow Venture Partners; Namarel Ventures; Inveniam

</em>Exact date not specified but occurred prior to April–October announcements in company news.

---

Investor Information

• Venture Capital & Angel Investors:
• Grow Venture Partners (lead)
• Namarel Ventures
• Inveniam Group
• Intempo Ventures is also listed as an investor on company materials.
• Public Grants & Programs:
• European Commission / European Innovation Council (EISMEA)
• Women TechEU program; Horizon Europe SCALEUP initiative
• ENISA loan support in Spain (expected in or after 2024)
• Additional research grants from Catalan Society of Cardiology and Instituto de Salud Carlos III.

---

Company Valuations

No public information is available regarding formal company valuations following these funding rounds.

---

Exit Events: IPOs, Buyouts, Acquisitions

As of May 2025:

• No documented IPOs.
• No public acquisition or buyout events reported.
• The company remains privately held with institutional backing through both venture investment and significant EU innovation grants.

---

Additional Recognitions Since Funding

Nimble Diagnostics received notable accolades: - Best SITE Innovation Award at the SITE Congress Barcelona in October 2023.

Winner at ePitching MedTech EIC event (2024).

These awards strengthen their reputation but do not directly relate to financing or exit activity.

---

Summary Table: Post-EIC Accelerator Fundraising Chronology

Event	Date	Amount
Private VC-led Seed Round	Q4–late Q3 ‘23	>€1M
EIC Accelerator Grant	Oct–Nov ‘23	€2.5M

</em>Sequence inferred based on company disclosures; exact dates may vary slightly due to ongoing reporting cycles.

There have been no further disclosed rounds above these amounts nor any exit events as of this writing.

---

Sources

• Nimble Diagnostics secures a €2.5 million grant from the EIC Accelerator programme
• Nimble Diagnostics secures a €2.5 million grant from the EIC Accelerator programme
• EIC Accelerator winners and statistics June 2023: NIMBLE DIAGNOSTICS SL
• NIMBLE Diagnostics Closed Funding of Over 1 million Euros
• funding archivos – Nimble Diagnostics
• INVESTORS – Nimble Diagnostics

3 The Press Releases

NIMBLE DIAGNOSTICS SL: Post-EIC Accelerator Funding Developments

NIMBLE DIAGNOSTICS SL, a Spanish MedTech startup, secured a €2.5 million grant from the EIC Accelerator in June 2023 to advance its non-invasive monitoring system for cardiovascular patients with implanted stents. The funding supports prototype development and the company’s first European clinical trial, aimed at detecting life-threatening complications early.

Key Updates Since the EIC Award

• Funding Milestones:
• Closed a pre-seed round exceeding €1 million, led by Grow Venture Partners, Namarel Ventures, and Inveniam Group.
• Received additional grants such as the ENISA loan (2024) and recognition under Horizon’s Women TechEU program.
• Technology Advancements:
• Developing the NIMBLE System, a proprietary medical device combining non-ionizing radiation and AI for continuous stent monitoring.
• Preparing preclinical testing and regulatory studies ahead of trials at Hospital Universitari Germans Trias i Pujol (2024).
• Awards & Recognition:
• Won the Best SITE Innovation Award (October 2023) for advancements in endovascular cardiology.
• Named a Top 20 Spanish company in active aging by La Caixa Foundation’s SILVER XXI Award (2023).

Leadership & Partnerships

The management team—including CEO Dr. Oriol Iborra Egea, CTO Susana Amorós Garcia de Valdecasas, and COO Andrés Ortega-Verdaguer—spearheaded fundraising efforts while collaborating with academic institutions like IGTP, UPC BarcelonaTech, and UB. Strategic investors include Intempo Ventures and public-private grants from EU programs^13.

---

Sources

• EIC Accelerator winners June 2023
• EIC Accelerator grant announcement | UB confirmation | Investors page | Funding details

4 The Technology Advancements

Nimble Diagnostics SL: Post-EIC Accelerator Progress and Capabilities

Since securing a €2.5 million EIC Accelerator grant in October 2023, Nimble Diagnostics SL has advanced its non-invasive stent monitoring technology, targeting cardiovascular, renal, and pulmonary stent complications. Below is an analysis of their progress across key areas:

---

Technological Advancements

The company’s NIMBLE System, which uses microwave-based electromagnetic signatures to detect stent blockages or fractures, has evolved from a probe-based prototype to an external antenna design for deeper tissue penetration and clinical feasibility. This shift improved accuracy in detecting restenosis (reblockage) and fractures by analyzing resonance frequency variations, as demonstrated in preclinical studies. Recent updates highlight its portability for use across hospital triage, post-implantation verification, and primary care follow-up.

---

Market Implementation & Clinical Trials

• Pilot Study: In April 2025, Nimble expanded a Barcelona-based pilot study to enroll 120 patients, focusing on validating the system’s diagnostic accuracy for stent malfunctions.
• Pivotal Trial Preparations: The company initiated groundwork for a late-2025 multinational pivotal trial to support regulatory approvals. These efforts aim to address the current standard of care’s reliance on invasive imaging (e.g., intravascular ultrasound) or symptom-driven follow-ups.

---

Intellectual Property & Publications

While no new patents or peer-reviewed studies are explicitly mentioned post-2023 grant award:

• Earlier research validated their microwave spectrometry approach in murine models (Scientific Reports)†‡.
• The company emphasizes proprietary algorithms for analyzing stent-specific electromagnetic signatures as a core innovation area.

---

Leadership & Recognition

Co-founders Dr. Oriol Iborra Egea (CEO) and Susana Amorós Garcia de Valdecasas (CTO) have steered the team toward clinical validation milestones since 2022. Their work earned the Best SITE Innovation Award in endovascular cardiology (October 2023), reinforcing industry confidence in their solution’s potential impact on preventative care globally.

---

Sources

• Nimble Diagnostics: HOME
• UB/IGTP/UPC Spin-off Announcement
• Technology Overview (Note: URL corrected from input data; original link here)
• Clinical Trial Expansion Update
• EIC Grant Announcement (Note: Original URL provided as source)
• Award Recognition Details (Original URL provided)

† Referenced murine model study is implied but not directly cited in available sources.
‡ No new peer-reviewed publications explicitly mentioned post-EIC funding.

5 The Partnerships and Customers

NIMBLE DIAGNOSTICS SL: Strategic Partnerships and Market Positioning Post-EIC Accelerator Funding NIMBLE DIAGNOSTICS SL, a Spanish medtech innovator, has solidified key partnerships and secured strategic funding to advance its non-invasive stent-monitoring technology. Below is an analysis of its collaborations, market positioning, and technological roadmap.

---

Partnerships and Investors

• Institutional Collaborations: NIMBLE operates as a spin-off involving three major entities: the Germans Trias i Pujol Research Institute (IGTP), Universitat Politècnica de Catalunya (UPC), and Universitat de Barcelona. These partnerships provide access to cardiology expertise, engineering resources, and clinical validation pathways.
• Investor Backing: Its €1M+ funding round (led by Grow Venture Partners, Namarel Ventures, and Inveniam Group) supports preclinical testing, regulatory studies, and a 2024 clinical trial at Hospital Universitari Germans Trias i Pujol. Additional grants include ENISA loans (2024) and recognition from the Catalan Society of Cardiology.
• European Initiatives: Participation in the 2023 Women TechEU program under Horizon EIE SCALEUP highlights its focus on gender-inclusive tech development.

---

Market Positioning Through Relationships

• Clinical Validation: Collaboration with Hospital Universitari Germans Trias i Pujol ensures real-world testing environments for its stent-monitoring device, enhancing credibility for future regulatory approvals (e.g., CE marking).
• Academic Integration: Ongoing ties with UPC facilitate access to engineering talent for prototyping optimizations, while IGTP’s cardiology expertise ensures alignment with unmet clinical needs.

---

Technology Advancement Pathways

• Funding Allocation: The secured capital accelerates preclinical work to achieve TRL 5-6 readiness ahead of human trials, focusing on early detection of stent-related complications like restenosis or thrombosis.
• Regulatory Strategy: Partnerships with public institutions like Instituto de Salud Carlos III provide frameworks for navigating EU medical device regulations.

---

Strategic Outlook

By leveraging academic-industrial synergies and venture capital backing, NIMBLE aims to position itself as a leader in preventative cardiology devices. Its collaborations ensure technical robustness while accelerating market entry through validated clinical pathways.

---

Sources
NIMBLE Diagnostics Closed Funding | Investors | Women TechEU Recognition | UPC Collaboration

6 The Hiring and Company Growth

NIMBLE Diagnostics SL Team Growth and Hiring Strategy Post-EIC Accelerator Funding NIMBLE Diagnostics, a Spanish MedTech spin-off developing non-invasive microwave-based stent monitoring technology, has strategically expanded its team to support regulatory milestones and commercialization efforts. While exact headcount figures remain undisclosed, the company’s team page lists nine core executives alongside specialized advisors, reflecting a multidisciplinary structure combining clinical, engineering, and business expertise[^1^].

Recent Growth and Key Hires
Since securing a €1M+ funding round in 2022 led by Grow Ventures[^4^], NIMBLE has prioritized roles critical to clinical validation and market access:

• Pol Gómez Puchades: Appointed Clinical Operations Manager to lead trials[^2^].
• Ana Pérez Bueno: Regulatory Affairs & Quality Assurance Manager overseeing compliance[^2^].
• David Anguiano Sanjurjo: Senior Telecommunications Engineer enhancing RF system development[^2^].

The company is currently raising a €12M Series A (€9M secured as of April 2025), with funds earmarked for scaling operations. While active hiring initiatives are not explicitly detailed, the expansion of specialized managerial roles suggests targeted recruitment in regulatory affairs, clinical operations, and engineering to meet 2025 commercialization goals.

Impact of Team Expansion
New hires strengthen NIMBLE’s capacity to transition from R&D to commercial readiness:

• Clinical Trials Acceleration: Gómez Puchades’ leadership ensures efficient trial execution at Germans Trias i Pujol Hospital[^.
• Regulatory Preparedness: Pérez Bueno’s expertise streamlines CE marking and FDA pathways ahead of the planned 2025 launch[^.
• Technical Innovation: Anguiano Sanjurjo’s RF systems work underpins device reliability for global deployments[^.

No major management changes have been reported since co-founders Dr. Oriol Iborra (CEO) and Susana Amorós (CTO) established the company in March 2022[^^7][^. The advisory board includes industry veterans like Peter Fitzgerald (cardiovascular devices) and Antoni Bayés Genís (clinical cardiology), providing strategic oversight during scale-up phases.[^^2]^

---

Sources
[NIMBLE Diagnostics Bringing Visibility to Vascular Implants | TEAM - Nimble Diagnostics | Nimble Diagnostics closes a financing round of 1M | NIMBLE System Overview | Microwave Spectrometry Technology | UB Spin-off Announcement

7 The Media Features and Publications

NIMBLE Diagnostics SL: A Pioneer in Non-Invasive Stent Monitoring

NIMBLE Diagnostics SL, a Spanish company and a recent winner of the EIC Accelerator funding, has made significant strides in the medical technology sector since receiving the award on June 21, 2023. The company specializes in developing innovative diagnostic tools for monitoring stents, which are crucial for patients with cardiovascular diseases.

Media Features and Publications

NIMBLE Diagnostics has been featured in various publications and media platforms for its groundbreaking technology. The company's microwave-based diagnostic device is highlighted for its ability to monitor implanted stents non-invasively, addressing a long-standing gap in vascular implant care. These publications emphasize the potential of NIMBLE's technology to improve patient outcomes by early detection of stent malfunctions.

Content from Publications

Publications have noted that NIMBLE Diagnostics' system uses microwave signals to assess stent integrity and patency, offering real-time data on blockages or fractures. This technology aims to optimize care pathways by enabling early intervention when needed and avoiding unnecessary procedures when not. The company's mission is to become the new standard of care for patients with implanted devices, significantly reducing healthcare costs and improving patient lives.

Podcasts and Interviews

The company's leadership, including CEO Oriol Iborra, has participated in several podcasts and interviews. These discussions highlight NIMBLE Diagnostics' vision and technological advancements in non-invasive stent monitoring. Oriol Iborra has explained how the company's technology can revolutionize patient care by allowing for early interventions and reducing serious complications.

Conference and Fair Visits

NIMBLE Diagnostics has actively participated in various conferences and fairs. Notably, the company presented its technology at the LSI Europe '24 Emerging Medtech Summit in Sintra, Portugal. Additionally, they successfully debuted at the 2024 Mobile World Congress in Barcelona, showcasing their vision to prevent major coronary ischemic events. NIMBLE Diagnostics also participated in the Barcelona Roadshow Pitch Competition, emphasizing their role in transforming patient care through early interventions.

Involvement in Events

The company is set to continue its engagement with the healthcare community through several upcoming events. These include participation in the LSI USA '25, LSI Asia '25, and LSI Europe '25, where they will further showcase their innovative technology and its potential impact on patient care.

Sources

• Non-Invasive Stent Complication Diagnostic Tool | LSI Europe '24
• NIMBLE Diagnostics Bringing Visibility to Vascular Implants
• Novel and Innovative Technology - NIMBLE Diagnostics
• Nimble Diagnostics, new CATALONIA.HEALTH members
• NIMBLE Diagnostics attends the 2024 Mobile World Congress
• Nimble Diagnostics: HOME
• Podcast with Oriol Iborra Egea, PhD
• Startup Pitch by Nimble Diagnostics | MedTech World
• dxnimble, autor en Nimble Diagnostic